Ruxolitinib Project

  • 30 December, 2022
  • By Rxilient

We are pleased to release the news that on 30 December 2022, that we have through Rxilient Medical Pte. Ltd. acquired a potential blockbuster innovative product in dermatology filed from CMS Aesthetics by entering into a sublicense and collaboration agreement obtaining the license for the development, production, registration and commercialization of Ruxolitinib cream in Taiwan and eleven countries in Southeast Asia (“Territory”), commencing on its effective date.

Ruxolitinib Cream is the only topical JAK inhibitor and the first vitiligo repigmentation drug approved by the U.S. FDA. Through this transaction, Rxilient brings a novel treatment option for patients with unmet medical needs in the Territory.

Ruxolitinib cream, a novel cream formulation of Incyte’s (NASDAQ: INCY) selective JAK1/JAK2 inhibitor ruxolitinib, is the first and only topical JAK inhibitor approved for use in the United States1. Ruxolitinib cream is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable2.  The Product is also approved in Europe for the treatment of adolescents and adults from 12 years of age with non-segmental vitiligo with facial involvement.

Reference:
  1. Drug approval information can be found on the FDA official website, as follows:
    https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older
  2. FDA Instructions for Use (IFU) of ruxolitinib cream
Disclaimer:
  1. This news/article is intended to share cutting-edge medical information and is only for reference by medical and health professionals for academic purposes. It is not intended to promote any products to you and is not for advertising purposes.
  2. This news/article does not recommend any drugs, medical devices and/or indications.
  3. The information involved in this news/article is for reference only. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the instructions for use.
Share:
reach us today

Your gateway to rxilient,
Get in touch with us